T-Wave Alternans Will Help ICDs Meet Market Potential – Cambridge Heart
This article was originally published in The Gray Sheet
Executive Summary
Further adoption of Cambridge Heart's Microvolt T-Wave Alternans (MTWA) non-invasive test for assessing risk of sudden cardiac death will boost the number of ICD-eligible patients referred to electrophysiologists, the company maintains